SAN DIEGO -- Treatment with investigational elisrasib, a next-generation KRAS G12C inhibitor, showed efficacy in patients ...

After a study revealed higher cancer and other risks with a JAK inhibitor in patients with rheumatoid arthritis, further ...

Patient- and physician-facing interventions together doubled the reductions in PPI use ...

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...

In patients with an atherosclerotic CVD event or at intermediate to high risk for one who were on statin therapy, a novel ...

A novel oral molecule significantly reduced inflammatory markers linked to development of arteriosclerotic cardiovascular ...

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors ...

Volatility is one of the things you’ll want to be prepared to address this season, depending on your nitrogen source. Nitrogen inhibitors, often referred to as stabilizers, are increasingly used by ...